Predictors of liver-related complications in patients with chronic hepatitis C

References

• Alter MJ. The epidemiology of hepatitis C in the west. Semin Liver Dis 1995; 15: 5–14.
   PubMed Web of Science ®Google Scholar
• El-Serag H, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Eng J Med 1999; 340: 745–50.
   PubMed Web of Science ®Google Scholar
• Farrell GC. Hepatocellular carcinoma after sustained re-sponse to Interferon in non-cirrhotic hepatitis C. Flaws in the cure, or a clue to the flaws? J Gastroenterol Hepatol 1999; 14: 833–7.
   PubMed Web of Science ®Google Scholar
• Deuffic S, Buffat L, Poynard T, Valleron A-J. Modelling the hepatitis C epidemic in France. Hepatology 1999; 29: 1596–601.
   PubMed Web of Science ®Google Scholar
• Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341–4.
   Google Scholar
• Khan MH, Farrell GC, Blyth K, Lin R, Weltman M, George J, et al. Which patients with hepatitis C develop compli-cations? Hepatology 2000; 31: 513–20.
   PubMedGoogle Scholar
• Seef LB. Natural history of hepatitis C. Hepatology 1997; 26 (Suppl 1): 21S–8.
   Google Scholar
• Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcino-genesis by Interferon Therapy. Ann Intern Med 1999; 131: 174–81.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka 0, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to Interferon therapy. Ann Intern Med 2000; 132: 517–24.
   PubMed Web of Science ®Google Scholar
• Seef LB. Natural history of hepatitis C. Am J Med 1999; 107(6B): 10S–5.
   Google Scholar
• Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test. Hepatology 1995; 21: 725–9.
   Google Scholar
• Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–72.
   PubMed Web of Science ®Google Scholar
• Hu K-Q, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311–6.
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–32.
   PubMed Web of Science ®Google Scholar
• Schiff E. The alcoholic patient with hepatitis C virus infection. Am J Med 1999; 107(6B): 95S–9.
   Google Scholar
• Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Eng J Med 1999; 340: 1228–33.
   PubMed Web of Science ®Google Scholar
• Hourigan LF, MacDonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215–9.
   PubMed Web of Science ®Google Scholar
• Casaril M, Stanzial AM, Tognella P, Pantalena M, Capra F, Colombari R, et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology 2000; 47: 220–5.
   PubMed Web of Science ®Google Scholar
• Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P. et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868–72.
   PubMed Web of Science ®Google Scholar
• Guechot J, Serfaty L, Bonnand AM, Chazouilleres 0, Poupon RE, Poupon R. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000; 32: 447–52.
   PubMed Web of Science ®Google Scholar
• Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28: 562–7.
   PubMedGoogle Scholar
• Bjero K, Skaug K, Haaland T, Freiland SS. Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. Q J Med 1999; 92: 433–41.
   Google Scholar
• Powell EE, Edwards-Smith, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828–33.
   PubMed Web of Science ®Google Scholar
• Mizokami M, Albrecht JK, Kato T, Onto E, Lai V, Goodman Z, et al. TT virus infection in patients with chronic hepatitis C virus infection-effect of primers, prevalence, and clinical significance. J Hepatol 2000; 32: 339–43.
   Google Scholar
• Davis GL. Hepatitis C virus genotypes and quasispecies. Am J Med 1999; 107(6B): 21S–6.
   Google Scholar
• Nagayama K, Kurozsaki, Miyasaka Y, Marumo F, Sato C. Characteristics of hepatitis C viral genome associated with disease progression. Hepatology 2000; 31: 745–50.
   Google Scholar
• Benhamou Y, Bochet M, Di Martino V, Frederic C, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054–8.
   PubMed Web of Science ®Google Scholar
• Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Eng J Med 1998; 338: 286–90.
   PubMed Web of Science ®Google Scholar